Evidence map›Paper›PMID 42127904›Full record

ArticleCell reports. Medicine2026

Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer.

Yuhui He, Haozhuo Guo, Bing Wang, Wenzhi Gao, Yisen Deng, Ying Zhao, Kunshan He, Xiaolong Liang, Jie Tian, Jianfeng Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuhui HeDepartment of Urology, China-Japan Friendship Hospital, Beijing 100029, China; Department of Urology, Peking University First Hospital, Beijing 100034, China; CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
Haozhuo GuoCAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
Bing WangDepartment of Urology, Peking University First Hospital, Beijing 100034, China; Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing 101599, China.
Wenzhi GaoDepartment of Urology, Peking University First Hospital, Beijing 100034, China; Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing 101599, China.
Yisen DengDepartment of Urology, China-Japan Friendship Hospital, Beijing 100029, China.
Ying ZhaoDepartment of Urology, China-Japan Friendship Hospital, Beijing 100029, China.
Kunshan HeCAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
Xiaolong LiangDepartment of Ultrasound, Peking University Third Hospital, Beijing 100096, China.
Jie TianKey Laboratory of Big Data-Based Precision Medicine, Beihang University, Beijing 100191, China. Electronic address: jie.tian@ia.ac.cn.
Jianfeng WangDepartment of Urology, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address: zryhyy1@126.com.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing 100034, China. Electronic address: pineneedle@sina.com.
Yang DuCAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China; The University of Chinese Academy of Sciences, Beijing 100080, China. Electronic address: yang.du@ia.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is a common malignancy, yet conventional white light cystoscopy (WLC) has suboptimal diagnostic accuracy. Nectin4, a membrane protein highly expressed in BC, is an attractive molecular imaging target. By conjugating indocyanine green (ICG) to enfortumab vedotin, we develop NECTIN4-ICG, a BC-specific fluorescence imaging probe. In BC mouse models, NECTIN4-ICG enables targeted detection and doubles the complete tumor resection rate. In an ex vivo study of 18 fresh human bladders yielding 82 specimens, NECTIN4-ICG-guided biopsy achieves 96.3% diagnostic accuracy. In a clinical trial involving 20 patients yielding 198 specimens, NECTIN4-ICG-guided biopsy achieves 96.0% diagnostic accuracy and 91.1% tumor margin detection, outperforming WLC (82.2% and 73.3%). NECTIN4-ICG also enables fluorescence-guided TURBT, enhancing real-time visualization, margin assessment, and carcinoma in situ detection with a favorable safety profile. This clinical trial is registered under ChiCTR2200067094 and ChiCTR2400092677.

Indexed as

Cell Adhesion MoleculesCystoscopyMolecular ImagingSurgery, Computer-AssistedUrinary Bladder NeoplasmsAgedAnimalsFemaleHumansIndocyanine GreenMaleMiceMiddle AgedNectinsCell Adhesion MoleculesIndocyanine GreenNECTIN4 protein, humanNectinsbladder cancerdiagnosisfluorescence molecular imagingindocyanine greennectin4transurethral resection of the bladder tumor

Identifiers

PMID42127904
PMCPMC13293966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.